OverviewSuggest Edit

GT Biopharma (formerly Oxis International) is engaged in the development of immunotherapies for cancer treatment. Its lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis. Its lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.

Multiple myeloma is a type of cancer that forms in white blood cells, and affects about 26,850 people annually in the USA causing about 11,240 deaths per year. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Multiple myeloma is also characterized by destructive lytic bone lesions (rounded, punched-out areas of bone), diffuse osteoporosis, bone pain, and the production of abnormal proteins which accumulate in the urine. Anemia is also present in most multiple myeloma patients at the time of diagnosis and during follow-up. Anemia in multiple myeloma is multifactorial, and is secondary to bone marrow replacement by malignant plasma cells, chronic inflammation, relative erythropoietin deficiency, and vitamin deficiency. Plasma cell leukemia, a condition in which plasma cells comprise greater than 20% of peripheral leukocytes, is typically a terminal stage of multiple myeloma and is associated with short survival.

According to the American Cancer Society there were approximately 231,840 new cases of invasive breast cancer last year in the USA and 40,290 deaths from breast cancer during the same period. Women represent 99% of all breast cancer patients. Breast cancer is treated by various combinations of surgery, radiation therapy, chemotherapy, and hormone therapy. TNBC is a type of breast cancer characterized by breast cancer cells that do not express estrogen receptors, progesterone receptors, or large amounts of HER2/neu protein. Approximately 10% - 20% percent of invasive breast cancers are diagnosed as triple-negative breast cancers. TNBC is more likely to affect younger people, African Americans or Hispanics, and those with a BRCA1 gene mutation. TNBC is insensitive to many of the most effective therapies available for the treatment of breast cancer including the HER2-directed therapy Herceptin® (trastuzumab), and endocrine therapies such as tamoxifen or the aromatase inhibitors. The relapse and survival rates of TNBC patients are shorter than for patients with other types of breast cancer. There is no current or pending drug therapy available for the treatment of TNBC.

TypePublic
Founded1965
HQTampa, FL, US
Websitegtbiopharma.com

Latest Updates

Employees (est.) (Dec 2018)3(-40%)
Revenue (FY, 2017)$0
Share Price (Feb 2021)$0.4 (+2%)
Cybersecurity ratingAMore

Key People/Management at GT Biopharma

Anthony J. Cataldo

Anthony J. Cataldo

Chairman, Chief Executive Officer & President
Jeffrey S. Miller

Jeffrey S. Miller

Consulting Chief Medical Officer
Bruce Wendel

Bruce Wendel

Vice Chairman & Independent Director
Michael Handelman

Michael Handelman

Chief Financial Officer
Gregory Berk

Gregory Berk

Independent Director
Martin Schroeder

Martin Schroeder

Consulting Chief Technology Officer
Show more

GT Biopharma Office Locations

GT Biopharma has offices in Tampa and Beverly Hills
Tampa, FL, US (HQ)
100 Ashley Dr S #600
Beverly Hills, CA, US
9350 Wilshire Blvd #203
Show all (2)

GT Biopharma Financials and Metrics

GT Biopharma Revenue

USD

Net income (Q2, 2020)

(8.8m)

EBIT (Q2, 2020)

(1.6m)

Market capitalization (5-Feb-2021)

40.4m

Closing stock price (5-Feb-2021)

0.4

Cash (30-Jun-2020)

851.0k

EV

64.8m
GT Biopharma's current market capitalization is $40.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

26.0k342.0k368.0k61.0k27.0k

Revenue growth, %

8%(83%)(56%)(100%)

Cost of goods sold

48.0k94.0k226.0k57.0k

Gross profit

(22.0k)248.0k142.0k4.0k27.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.0k2.0k1.0k1.0k120.0k88.0k56.0k183.0k25.0k3.0k7.0k20.0k

Cost of goods sold

15.0k8.0k1.0k32.0k69.0k12.0k123.0k17.0k5.0k

Gross profit

(14.0k)(6.0k)1.0k88.0k19.0k44.0k60.0k8.0k(2.0k)7.0k20.0k

Gross profit Margin, %

(1400%)(300%)100%73%22%79%33%32%(67%)100%100%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

92.0k123.0k43.0k855.0k47.0k19.0k576.0k60.0k28.0k

Accounts Receivable

40.0k4.5k

Prepaid Expenses

30.0k246.0k

Inventories

12.0k59.0k42.0k357.1k251.8k415.8k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

89.0k120.0k5.0k61.0k11.0k4.0k1.0k664.0k1.4m125.0k42.0k30.0k355.0k154.0k235.0k39.0k2.7m2.9m1.1m1.2m51.0k264.0k313.0k5.0k851.0k

Accounts Receivable

30.0k5.0k

Prepaid Expenses

105.0k343.0k12.0k12.0k12.0k1.0k2.0k2.0k2.0k2.0k2.0k2.0k15.0k27.0k22.0k24.0k183.0k120.0k

Inventories

12.0k92.0k94.0k120.0k40.0k42.0k26.0k26.0k
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.7m)(5.2m)(501.0k)(23.5m)(32.7m)21.0m(143.2m)(259.2m)(38.6m)

Depreciation and Amortization

23.0k2.0k1.0k2.0k7.0k4.0k

Inventories

(47.0k)17.0k42.0k(20.0m)

Accounts Payable

533.0k480.0k(276.0k)880.0k2.8m1.4m136.0k3.2m
Quarterly
USDQ2, 2011

Debt/Equity

-0.2 x

Debt/Assets

5.3 x
Show all financial metrics

GT Biopharma Operating Metrics

FY, 2016

Patents Issued

2

Patents Pending

2
Show all operating metrics

GT Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

GT Biopharma Online and Social Media Presence

Embed Graph

GT Biopharma News and Updates

GT Biopharma (OTCQB: GTBP) Announces Corporate Update Conference Call

BEVERLY HILLS, Calif., Jan. 4, 2021 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform announces that it will be holding a shareholder update...

GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers

BEVERLY HILLS, Calif., Dec. 28, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform is pleased to announce the filing of U.S. and...

GT Biopharma Submits Application for Uplisting to the NASDAQ Capital Market

Anthony Cataldo, CEO and Chairman of GT Biopharma commented, "It is our belief that uplisting to a major exchange will allow a broader base of worldwide institutions, funds and retail investors to participate in our future success. Moreover, with the success of the data most recently presented at th…

GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer

Prior to joining the Company, Mr. Handelman served as Chief Financial Officer of Iovance Biotherapeutics, Inc.read more

GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting

Session Name: 704. Immunotherapies: Beyond T to NK Session Date: Saturday, December 5, 2020 Session Time: 7:30 AM - 9:00 AM Eastern Time Presentation Time: 8:00 AM Eastern Time.read more

GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills

TAMPA, Florida, Oct. 22, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform, announced today that Drs. Jeffrey Miller, Martin Felices and Pippa...
Show more

GT Biopharma Blogs

GT Biopharma Announces Closing of Private Placement Financing and Provides Business Update

Corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational 2019 Company on track to report topline Phase 2a data of GTB-1550 this quarter First-in-class TriKE, GTB-3550, on track for H1 2019 commencement of first-in-human Phase 1 study for th…

GT Biopharma, Inc. to Present at Biotech Showcase™ 2019

– Presentation with live audio webcast, Tuesday, January 8, 2019 at 11:30 AM PST – LOS ANGELES, Dec. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on innovative treatme…

GT Biopharma Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition

– Company’s proprietary TriKE product candidates have the potential to serve as a relatively safe, cost-effective, and easy-to-use therapy for refractory/relapsed AML, high-risk MDS and advanced systemic mastocytosis – – Positive preclinical findings highlight the clinical potential of the CLEC12…

GT Biopharma Announces Presentation of Two Abstracts at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition

LOS ANGELES, Nov. 20, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on innovative treatments based on the Company's proprietary NK-engager and Bispecific Antibody Drug Conjug…

GT Biopharma's Chairman and Chief Executive Officer, Raymond W Urbanski MD, PhD, Provides Further Insight into the Recent Activity in the Natural Killer Cell (NK) Space

LOS ANGELES, CA / ACCESSWIRE / October 4, 2018 / GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary NK-engager and Bispecific Antibody Drug Conjugate platforms. Only a few weeks ag…

GT Biopharma Announces Postive Results For Two Next Generation Trikes In Solid Tumors

LOS ANGELES, CA / ACCESSWIRE / September 13, 2018 / GT Biopharma Inc. (OTCQB: GTBP) and (Euronext Paris: GTBP) announced today the positive results for two next generation Trispecific Killer Engagers (TriKEs) in solid tumors. These efforts were headed by Dr. Daniel Vallera, Director, Section of Mole…
Show more

GT Biopharma Frequently Asked Questions

  • When was GT Biopharma founded?

    GT Biopharma was founded in 1965.

  • Who are GT Biopharma key executives?

    GT Biopharma's key executives are Anthony J. Cataldo, Jeffrey S. Miller and Bruce Wendel.

  • How many employees does GT Biopharma have?

    GT Biopharma has 3 employees.

  • Who are GT Biopharma competitors?

    Competitors of GT Biopharma include Biogen, MyoKardia and Athersys.

  • Where is GT Biopharma headquarters?

    GT Biopharma headquarters is located at 100 Ashley Dr S #600, Tampa.

  • Where are GT Biopharma offices?

    GT Biopharma has offices in Tampa and Beverly Hills.

  • How many offices does GT Biopharma have?

    GT Biopharma has 2 offices.